Cagrilintide monotherapy may be a good fit if: You have tried GLP-1 receptor agonists and could not tolerate the vomiting You prefer a compound with a very low treatment discontinuation rate You are comfortable with elevated injection site reactions Your weight loss target is moderate (10-15% body weight) You want to try a novel mechanism of action (amylin vs GLP-1) CagriSema may be worth considering if: You need more aggressive weight loss (15-20%+) You tolerated GLP-1 receptor agonists reasonably well You can manage more significant GI side effects The additional weight loss justifies the additional side effect burden for your situation You should consider alternatives if: Injection site reactions are a major concern for you You have history of pancreatitis or severe GI conditions You have personal or family history of medullary thyroid carcinoma You need an FDA-approved option with extensive post-marketing safety data Fatigue would significantly impact your work or training Our best peptides for weight loss guide and best fat burning peptide comparison can help researchers who determine that cagrilintide is not the right fit explore other options
Current Status and Future Directions Some commercial entities have marketed AOD9604 as a research compound or nutraceutical ingredient, though such uses exist in regulatory gray areas
Am J Physiol Lung Cell Mol Physiol 292(2):L824L832
Patients want alternatives to long-term steroid use GLP-1 modulation may offer a pathway to reduced inflammation without the side effects of immunosuppressants
The results can last for up to a year
The presence of dipeptide glycylglycine as a -glutamyl acceptor increased the deglutamylation activities of AsGGT1, AsGGT2, and AsGGT3 ( Figure 5 ), showing that these GGTs catalyze transpeptiation more efficiently than hydrolysis, as in GGTs from Arabidopsis and onion (Storozhenko et al., 2002
